Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. - Test2 - elhamkhani - TriplyDB

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.

http://www.wikidata.org/entity/Q30559887

about

Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli.Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery.Glycoconjugate vaccine containing Escherichia coli O157:H7 O-antigen linked with maltose-binding protein elicits humoral and cellular responses.Glycoarrays with engineered phages displaying structurally diverse oligosaccharides enable high-throughput detection of glycan-protein interactions Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins Chicken Anti-Campylobacter Vaccine - Comparison of Various Carriers and Routes of Immunization.Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific Antibodies.Engineering and Dissecting the Glycosylation Pathway of a Streptococcal Serine-rich Repeat Adhesin Biofilms: an advancement in our understanding of Francisella species.Increased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering.Functional analysis of N-linking oligosaccharyl transferase enzymes encoded by deep-sea vent proteobacteria.Implications of plant glycans in the development of innovative vaccines.Life sciences today and tomorrow: emerging biotechnologies.Bacteria like sharing their sweets.In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.Adaptive Immunity to Francisella tularensis and Considerations for Vaccine Development.Potential targets for next generation anti-microbial glycoconjugate vaccines.Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13

P2860

Q27336832-07C6A4F7-2058-4A51-B8B1-2CB32608A336 Q28831290-BD08E536-65BF-49F4-AE08-945960AAC718 Q33965527-6D09962C-21B3-4DF6-BF9B-24A257C42290 Q34066431-948D07B5-7EA3-4155-AD72-2F39F65E48DD Q35039981-8A5E2B31-1832-43C3-B689-5ABE52432AD8 Q36496166-1BAE6E8E-F795-4DBA-8893-E4802A232CC3 Q36915598-15E924F6-D16F-457D-962B-D0CD89FB9895 Q37425396-6769C8E5-EE9B-4CAC-A483-A2D9E1275D49 Q37551411-42EE2735-A646-4791-9BB9-DC71CBD644CF Q37587015-6FC7281D-57B2-4B69-9722-785C35E56280 Q38300058-41520F65-781B-4F46-9222-5C97A1A5FC51 Q38627991-843DADC7-0DAF-4F77-A843-86E451A5FFB9 Q38738762-1F79E91A-83B8-42EA-8A2E-F9E9AB7EAF18 Q38845763-074E5FD7-22CF-4CA2-8DAB-3B110706EC98 Q38957342-9F32D2FF-E69C-4F5E-9900-D808EB30AB5A Q42120657-F6BD27E3-19D4-4F32-81DF-F1B9AC1CC355 Q52571082-7660A3D3-19E6-4FB3-B7B5-F230E0A00356 Q53701548-E33FD263-38E6-4EE8-8FC7-E9F485456675 Q55310096-B6A7AAD6-2051-4FDD-A79B-2066D7E2EF6C Q58587115-3A0D863F-6500-489E-A5E5-8F6CF645F6BC

P2860

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.

http://www.wikidata.org/entity/Q30559887

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Exploitation of bacterial N-li ...... gainst Francisella tularensis.

@ast

Exploitation of bacterial N-li ...... gainst Francisella tularensis.

@en

type

label

Exploitation of bacterial N-li ...... gainst Francisella tularensis.

@ast

Exploitation of bacterial N-li ...... gainst Francisella tularensis.

@en

prefLabel

Exploitation of bacterial N-li ...... gainst Francisella tularensis.

@ast

Exploitation of bacterial N-li ...... gainst Francisella tularensis.

@en

P1433

Q30559887-E5386876-9356-4372-B1C9-0F2092EC1CED

P1476

Q30559887-4EB75322-8FCD-47C7-845F-DD0818D4EEF4

P2093

Q30559887-3DAD301B-BE91-437A-855C-6C0F6365B029

Q30559887-5B14C9FC-6E15-410F-9379-27AA858CFEE2

Q30559887-6EA0230F-E556-47B9-B717-262C4E44D9C7

Q30559887-7E709A1B-0D50-460C-B38D-E3411BBE7123

Q30559887-A75BB7E9-36AC-47CE-AF78-7EBE3962CF6D

Q30559887-AC27B437-9DF5-4E5A-9BB1-AEDDA3A1A51E

Q30559887-CC634CFF-DD66-4E67-8294-4DE845B8D22A

Q30559887-D6E6C865-AC97-4C87-823B-FBF7DB20E5C4

Q30559887-E328FA48-3565-4FFF-B4A0-EC481FFD1529

P2860

Q30559887-03865EA8-A9E0-439F-8C45-F495447FE5A4

Q30559887-12B24084-70CC-4786-AA6E-F7DFBD72304A

Q30559887-163C2115-0CBA-4BA8-B192-69A6D0DF7CC2

Q30559887-222AED5C-7C28-4EA2-8F2B-927103CA28D7

Q30559887-27662FFD-4CD0-4586-A185-987247D091CD

Q30559887-2A95D999-CC67-4FE5-95F1-8E71D944A6A1

Q30559887-3000F3C9-D920-4D65-A735-A119F3C240BD

Q30559887-399C48EF-3822-4045-9FAB-330BF11B70BA

Q30559887-4445169F-882C-43DE-A67C-45B7B91C8F61

Q30559887-4C641A80-F4BC-4202-9B75-A79836A8B7B1

P304

Q30559887-773EC352-7ADC-40C8-B219-E247152C002E

P31

Q30559887-40B51984-2156-4330-AC89-714989B84B52

P356

Q30559887-D482AD57-F92E-4CB5-96B8-C4258A696F27

P433

Q30559887-55A56B0F-F1D3-410C-825E-391938D04B3D

P478

Q30559887-FF08E839-9733-46DF-AC5A-6B41493C1B5F

P50

Q30559887-B181BE92-6307-4F3E-A45F-E0A2303586EA

P577

Q30559887-47C635B0-C5F0-463D-8765-B0B0FC5C933B

P5875

Q30559887-A796E25C-B7F4-444D-938C-28277A634594

P698

Q30559887-DE6F8635-8CBF-4CBD-B488-0725512B4420

P921

Q30559887-58DD4792-C541-4C9A-B422-974AC3411B95

P932

Q30559887-2AA5A86B-63BF-49B1-ADB3-F5D728A8A93B

P356

P1433

P1476

Exploitation of bacterial N-li ...... gainst Francisella tularensis.

@en

P2093

Diane Williamson

http://www.w3.org/2001/XMLSchema#string

Dominic C Mills

http://www.w3.org/2001/XMLSchema#string

Joann L Prior

http://www.w3.org/2001/XMLSchema#string

Jon Cuccui

http://www.w3.org/2001/XMLSchema#string

Madeleine G Moule

http://www.w3.org/2001/XMLSchema#string

Rebecca M Thomas

http://www.w3.org/2001/XMLSchema#string

Riccardo V D'Elia

http://www.w3.org/2001/XMLSchema#string

Thomas R Laws

http://www.w3.org/2001/XMLSchema#string

Timothy P Atkins

http://www.w3.org/2001/XMLSchema#string

P2860

Production of glycoprotein vaccines in Escherichia coli

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli.

Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccine.

Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis.

The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality.

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.

Tularemia as a biological weapon: medical and public health management.

N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli.

Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.

P304

130002

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1098/RSOB.130002

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236931755

http://www.w3.org/2001/XMLSchema#string

P698

23697804

http://www.w3.org/2001/XMLSchema#string

P921

P932

3866875

http://www.w3.org/2001/XMLSchema#string